Condition

Primary IgA Nephropathy clinical trials and research

• 6Clinical trials
• 35Countries

Newest Primary IgA Nephropathy clinical trials

All recruiting trials (6)

• Long-term safety and tolerability of HRS-5965 in primary IgA nephropathy

  This study tests whether HRS-5965 capsules are safe to use over the long term and whether they can reduce 24-hour urinary protein and slow eGFR decline in adults with primary IgA nephropathy who previously completed or stopped during maintenance.

  Recruiting Phase 2 Chengdu Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07582133

• YKST02 for adults with primary IgA nephropathy.

  This trial will test whether intravenous YKST02 is safe and can reduce urine protein in adults with primary IgA nephropathy who have persistent proteinuria despite standard treatment.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07498673

• SHR-2173 for people with primary IgA nephropathy

  This trial will test whether SHR-2173 injections can reduce proteinuria and protect kidney function in adults with primary IgA nephropathy compared with placebo over 48 weeks.

  Recruiting at 2 sites Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangdong and 1 other locations · NCT07354932

• Tonsil removal plus immunosuppression for high-risk IgA nephropathy in Caucasian adults

  This trial will see if removing the tonsils combined with immunosuppressive medicine helps Caucasian adults with high-risk IgA nephropathy preserve kidney function and reduce proteinuria.

  Recruiting at 2 sites St. Petersburg State Pavlov Medical University · Saint Petersburg and 1 other locations · NCT07074951

• HRS-5965 capsule for primary IgA nephropathy

  This Phase 3 trial will test whether HRS-5965 capsules reduce proteinuria and are safe for people with biopsy-confirmed primary IgA nephropathy who have persistent proteinuria and eGFR ≥30.

  Recruiting Phase 3 Chengdu Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07014826

• Long-term safety evaluation of iptacopan for patients with primary IgA nephropathy

  This study is testing the long-term safety of a drug called iptacopan for people with primary IgA nephropathy who have already participated in earlier trials.

  Recruiting Phase 3 Novartis · Glendale, Arizona and 160 other locations · NCT04557462

Related topics

Quick answers

How many Primary IgA Nephropathy clinical trials are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 35 countries. The most sites are in China (5 trials), Russia (2 trials), Argentina (1 trial), Australia (1 trial), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2, Phase 3: 2, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →